Abstract
The use of neoadjuvant therapy (NAT) for operable breast cancer (BC) has progressively increased over time and it is today recommended by major guidelines. The achievement of a pathological complete response (pCR) is associated with an improved outcome. As a consequence new strategies are required to early identify patients who will not respond. In this persepctive, metabolomics may represent an innovative technology to identify host related factors correlated with outcome. In this research we evaluate the use metabolomics analysis coupled to artificial intelligence to predict treatment outcome for BC patients undergoing NAT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
